Investigational drug · Phase 3
CTP-543
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Alopecia Areata.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
21
Any phase or sponsor naming "CTP-543"
First trial start
2019
Apr 4, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "CTP-543", any sponsor or status.
- Phase 113
Conditions studied
As listed on its trial records.
- Alopecia Areata
Approved drugs for the same conditions: Alopecia areata · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "CTP-543" as an intervention, largest first.
- Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataPivotal-lookingActive, not recruiting
Sun Pharmaceutical Industries, Inc.Industry
NCT03898479 · 1,000 participants (planned) · Start Apr 4, 2019 · Primary completion May 2027
Drug: CTP-543 · For: Alopecia Areata
Sites: Birmingham, Alabama; Phoenix, Arizona; Scottsdale, Arizona · 91 sites in all
- Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)Pivotal-lookingCompleted
Concert PharmaceuticalsIndustry
NCT04518995 · 706 participants · Start Nov 23, 2020 · Primary completion Apr 19, 2022
Drug: CTP-543 matching placebo; CTP-543 and 1 more · For: Alopecia Areata
Sites: Birmingham, Alabama; Bakersfield, California; Encinitas, California · 72 sites in all
- Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA2)Pivotal-lookingCompleted
Concert PharmaceuticalsIndustry
NCT04797650 · 517 participants · Start Jun 10, 2021 · Primary completion Jun 8, 2022
Drug: CTP-543 matching placebo; CTP-543 · For: Alopecia Areata
Sites: Phoenix, Arizona; Fort Smith, Arkansas; Los Angeles, California · 63 sites in all
- European Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia AreataPivotal-lookingCompleted
Sun Pharmaceutical Industries, Inc.Industry
NCT05041803 · 407 participants · Start Oct 19, 2021 · Primary completion Jul 18, 2024
Drug: CTP-543 · For: Alopecia Areata
Sites: Brest, France; Nice, France; Bordeaux, France · 39 sites in all
- A Study to Evaluate the Durability of Response of CTP-543 in Adult Patients With Moderate to Severe Alopecia AreataPivotal-lookingCompleted
Concert PharmaceuticalsIndustry
NCT04784533 · 317 participants · Start Feb 26, 2021 · Primary completion May 16, 2023
Drug: CTP-543; Placebo · For: Alopecia Areata
Sites: Birmingham, Alabama; Scottsdale, Arizona; Bakersfield, California · 39 sites in all
- Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia AreataPivotal-lookingCompleted
Concert PharmaceuticalsIndustry
NCT03137381 · 149 participants · Start Aug 9, 2017 · Primary completion Jul 8, 2019
Drug: CTP-543; CTP-543 matching placebo · For: Alopecia Areata
Sites: Irvine, California; Rancho Mirage, California; Redwood City, California · 13 sites in all
Concert PharmaceuticalsIndustry
NCT02777008 · 77 participants · Start May 2016 · Primary completion Dec 2016
Drug: CTP-543; Placebo for CTP-543 · For: Healthy
Sites: Adelaide, Australia
- Efficacy and Tolerability Study of Two Dosing Regimens of CTP-543 in Adults With Alopecia AreataCompleted
Concert PharmaceuticalsIndustry
NCT03941548 · 66 participants · Start May 24, 2019 · Primary completion Apr 10, 2020
Drug: CTP-543; CTP-543 Matching Placebo · For: Alopecia Areata
Sites: Centennial, Colorado; Tampa, Florida; Plainfield, Indiana · 12 sites in all
- Efficacy and Tolerability Study of Two Dose Regimens of CTP-543 in Adults With Alopecia AreataCompleted
Concert PharmaceuticalsIndustry
NCT03811912 · 57 participants · Start Mar 21, 2019 · Primary completion Nov 21, 2019
Drug: CTP-543; CTP-543 Matching Placebo · For: Alopecia Areata
Sites: Irvine, California; San Francisco, California; New Haven, Connecticut · 10 sites in all
- A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompleted
Concert PharmaceuticalsIndustry
NCT05192369 · 48 participants · Start Jan 4, 2022 · Primary completion Jan 28, 2022
Drug: CTP-543; CTP-543 and 2 more · For: Healthy Volunteers
Sites: Miami, Florida
Newest research
PubMed records naming it or its code names, newest first.
- Evaluation of the efficacy and treatment-emergent adverse events of deuruxolitinib for moderate to severe alopecia areata: a dose-ranging meta-analysis of 1,372 randomized patients.
Kalantan M, Bashrahil B, Aljuaid A, et al. · Front Med (Lausanne) 2025
- Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
Dainichi T, Iwata M, Kaku Y · J Dermatol 2024
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta-analyses of clinical trials.
Gupta AK, Wang T, Bamimore MA, et al. · J Cosmet Dermatol 2023
- Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata.
King B, Mesinkovska N, Mirmirani P, et al. · J Am Acad Dermatol 2022
- Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B, Ko J, Forman S, et al. · J Am Acad Dermatol 2021
- JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF, Sinclair R · Expert Rev Clin Pharmacol 2020
Also in development for Alopecia Areata
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- RezpegaldesleukinNKTR-358, REZPEGPhase 34 trials
Nektar Therapeutics · Moderate-to-Severe Atopic Dermatitis, Moderate to Severe Atopic Dermatitis, Alopecia Areata
- ADX-914bempikibartPhase 22 trials
Q32 Bio Inc. · Atopic Dermatitis, Alopecia Areata
- LY4005130Phase 22 trials
Eli Lilly · Alopecia Areata, Vitiligo, Non-Segmental Vitiligo (NSV)
- LAD603Phase 21 trial
Almirall, S.A. · Alopecia Areata
- NXC736Phase 21 trial
NEXTGEN Bioscience · Alopecia Areata
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.